Exelixis announces zanzalintinib in combination with an immune checkpoint inhibitor improved overall survival in STELLAR-303 phase 3 pivotal trial in patients with metastatic colorectal cancer.

A new study from US scientists has predicted a huge increase in this killer cancer-and there's one group in particular at risk.